Proteome Regulatory News (PRM)

Proteome Sciences plc

AGM Statement

28 June 2013 - Our commercial activities are benefiting from our technology development and the rapid increase in the numbers of biomarkers covered by our assays that doubled to over 100 in 2012. SysQuant® cell signalling pathway assays introduced this year will extend these further and should make a considerable contribution to our assay portfolio. This is reflected in biomarker services in revenue particularly through the major strategic contract announced earlier this month and through a broad and growing pipeline of contracts, enquiries and quotations.

Licensing discussions are expected to benefit from the excellent results coming through this year from CK1D that will be presented at the main Alzheimer's meeting in July, strongly supported by the considerable improvement in performance from two new peptide panels announced in the preliminary results for Alzheimer's disease and mild cognitive impairment (MCI), with further developments anticipated from our stroke biomarkers.

Outstanding data was presented at the June ASMS meeting using TMT® which now appears to be established as the reagent of choice for key opinion leaders in the field. The growing range of products and applications should accelerate and convert more widely the use of TMT® into mainstream biology and additional revenue.

We have again been made aware of certain speculative and inappropriate comments regarding our US biomarker patent portfolio in the light of recent US court rulings on patent eligibility, in particular the court's recent ruling against Myriad that patents will not be allowed on genes. This has no bearing on Proteome Sciences intellectual property. Shareholders will be pleased to know that we received subsequent notification this week from the US Patent and Trademark Office of the allowance of a new patent in Huntington's disease. We conclude that these decisions do not change the status of our issued and pending US applications or impact our granted US patents which continue to remain in good standing.

We expect a strong performance over the year from licences, products and services as we continue to raise our corporate and research profile and this should lead to a sharp increase in Group revenue in 2013.

Ends

For further information please contact:

Notes to Editors:

About Proteome Sciences

Proteome Sciences is a global leader in applied proteomics and peptidomics offering high sensitivity, proprietary technologies for protein and peptide biomarker discovery, validation and assay development. Its PS Biomarker Services™ uses isobaric and isotopic Tandem Mass Tag® (TMT®) workflows developed on the latest Orbitrap® Velos and TSQ Vantage mass spectrometers to deliver rapid, robust and reproducible biomarker assay development for customers in the pharmaceutical, diagnostic and biotechnology sectors. Services are provided from its ISO 9001: 2008 accredited facilities in Frankfurt, Germany. By combining Selected Reaction Monitoring (SRM) and TMT® workflows highly multiplexed assays can be developed rapidly and are suitable for screening hundreds of candidate biomarkers in larger validation studies and can be transferred for immunoassay development. The Company's own research has discovered a large number of novel protein biomarkers in key human diseases and is focused mainly in neurological/neurodegenerative conditions and in cancer. It has discovered and patented blood biomarkers, including Alzheimer's disease, stroke, brain damage and lung cancer for diagnostic and treatment applications that are available for license or are already outlicensed. Proteome Sciences, based in Cobham, UK, with facilities in London and Frankfurt, delivers outsourced proteomics services and proprietary biomarkers/biomarker

assays to pharmaceutical, biotechnology and diagnostics companies.

Visit: http://www.proteomics.com